Latest | F'cast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | -358.6% | n/a |
ROCE | n/a |
Latest | F'cast | |
---|---|---|
P/E | n/a | n/a |
PEG | n/a | n/a |
Pr/Revenue | 35.3 | n/a |
Pr/Book | 34.2 |
Latest | F'cast | |
---|---|---|
Revenue | -50.9% | n/a |
PBT | n/a | n/a |
EPS | n/a | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Jun-21 | 1.60 | (2.91) | (3.92)p | n/a | n/a | n/a | n/a | 0.0% |
30-Jun-22 | 4.04 | (2.64) | (3.24)p | n/a | n/a | n/a | n/a | 0.0% |
30-Jun-23 | 1.75 | (8.30) | (11.35)p | n/a | n/a | n/a | n/a | 0.0% |
30-Jun-24 | 0.86 | (3.14) | (0.71)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Major top 3 global pharma contract win | 08-Oct-2025 | 07:00 | RNS |
Notification of dealings by a director/PDMR | 09-Sep-2025 | 07:00 | RNS |
Therapeutic development agreement with Invizius | 02-Sep-2025 | 07:00 | RNS |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 1.13p |
Change Today | 0.025p |
% Change | 2.27 % |
52 Week High | 1.30p |
52 Week Low | 0.21p |
Volume | 14,606,972 |
Shares Issued | 2,696.98m |
Market Cap | £30.34m |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No dividends found |
Time | Volume / Share Price |
16:29 | 21,422 @ 1.10p |
16:24 | 443,458 @ 1.13p |
16:22 | 79,881 @ 1.10p |
16:17 | 51,040 @ 1.10p |
16:13 | 61,433 @ 1.12p |
CEO | Arron Tolley |
CFO | Andrew Rapson |
You are here: research